Sodium intake was almost linearly associated with SBP and DBP, without a threshold for low or high sodium exposure. The effect of sodium reduction on BP was more pronounced in individuals with hypertension.

This study used data from four community-based cohort studies and investigated the relation between SBP and incident CVD. Increasing CVD risk was observed beginning at lower SBP thresholds in women than in men.

Global CVD burden has increased in almost all regions outside high-income countries. The increase was largely due to population growth and aging. In addition, attribution of risk factors like SBP, BMI, and dietary risk increased worldwide.

A study of network approaches with clinical and pre-clinical validation showed that NOX5-induced uncoupling of endothelial NO synthase is a causal mechanism of an age-related hypertension endotype.

Compared to those who reported no alcohol intake, T2DM patients with moderate (>7 drinks/week) and heavy (>14 drinks/week) consumption had increased risk of elevated BP, hypertension grade I and hypertension grade 2.

ESC 2020 A study including 48 RCTs demonstrated that lowering of each 5 mmHg SBP resulted in 10% reduction of major CV events, regardless of baseline SBP and CVD status.

ESC 2020 Blood pressure-lowering reduces the risk of major CV events similarly in those with and without CVD and irrespectively of baseline SBP.

Presence of coronary artery calcium and risk of incident ASCVD events increased with increasing SBP levels in individuals with a SBP between 90 and 129 mmHg and no other traditional ASCVD risk factors.

In a case-control study of Chinese adults divided in age groups, earlier onset of hypertension was associated with higher risk of all-cause mortality and a trend for higher risk of CVD.

Reduction of antihypertensive medication in patients ≥80 years who were on ≥2 antihypertensive medication was noninferior to usual care with regard to SBP control at 12 weeks.

This study showed that a SBP of 120 to 129 mmHg was associated with the lowest risk of adverse outcomes in HFpEF. SBP lowering does not explain the treatment effects of sacubitril/valsartan.

The ESC Council on Hypertension has released a statement, strongly recommending to continue treatment of ACEi and ARBs in times of the COVID-19 pandemic, as evidence for harmful effects of these drugs in context of COVID-19 is lacking.